Kleefstra Syndrome

Kleefstra syndrome (KS) is a rare genetic disorder that affects development and involves many body systems. It is caused by mutations or deletions in the EHMT1 gene on chromosome 9, which encodes a protein that regulates gene expression. KS affects approximately 1 in 50,000 to 100,000 live births and has a wide range of clinical features and symptoms. The most common features include developmental delay, intellectual disability, speech impairment, hypotonia (low muscle tone), and distinctive facial features. KS can also cause various health problems, such as seizures, hearing loss, heart defects, sleep disorders, kidney defects, gastrointestinal problems, and respiratory infections. The severity and spectrum of KS vary among individuals with different types and sizes of genetic changes.

Clinical Features of Kleefstra Syndrome

The clinical presentation of Kleefstra syndrome (KS) is variable and heterogeneous, depending on the type and size of the genetic change affecting the EHMT1 gene. However, some common features and symptoms can be observed in most individuals with KS. These include physical characteristics, developmental and behavioral aspects, and medical complications and comorbidities.

The physical characteristics of KS are often noticeable at birth or early infancy. They include microcephaly, brachycephaly, synophrys, hypertelorism, midface hypoplasia, anteverted nares, prognathism, everted lips, macroglossia, and other distinctive facial features. Some individuals may also have a high birth weight and childhood obesity. The developmental and behavioral aspects of KS are usually evident in early childhood. They include developmental delay, intellectual disability, speech impairment, hypotonia (low muscle tone), and autism spectrum disorders. Most individuals with KS have severely limited or absent speech, and may communicate with gestures or sounds. Some may develop a few words or phrases later in life. Many individuals with KS have features of autism or related disorders, such as impaired social interaction, repetitive behaviors, and restricted interests. Some may also exhibit apathy or catatonia in adolescence.

The medical complications and comorbidities of KS are diverse and may affect various body systems. They include seizures, hearing loss, heart defects, sleep disorders, kidney defects, gastrointestinal problems, respiratory infections, and other health problems. Seizures are common in KS and may occur at any age. They can be controlled with antiepileptic drugs in most cases. Hearing loss can be sensorineural (caused by damage to the inner ear or nerve pathways) or conductive (caused by blockage or fluid in the middle ear). Heart defects can range from mild to severe and may require surgical intervention. Sleep disorders can include insomnia, sleep apnea, restless legs syndrome, and parasomnias. Kidney defects can include renal hypoplasia, hydronephrosis, vesicoureteral reflux, or renal failure. Gastrointestinal problems can include gastroesophageal reflux disease (GERD), constipation, diarrhea, vomiting, or feeding difficulties. Respiratory infections can be recurrent and severe, leading to pneumonia or bronchitis.

Clinical Diagnosis and Treatment Options of Kleefstra Syndrome

The clinical diagnosis of Kleefstra syndrome (KS) is based on the detection of a genetic change in the EHMT1 gene on chromosome 9, which regulates gene expression. This can be done by various methods, such as molecular cytogenetics, DNA sequencing, or MLPA. These methods have different strengths and weaknesses, such as sensitivity, specificity, cost-effectiveness, availability, etc. The diagnosis of KS also requires clinical features and symptoms that are specific to the disorder, such as distinctive facial features, developmental delay, intellectual disability, speech impairment, hypotonia, and other health problems. However, these features may overlap with other syndromes, such as Angelman syndrome. Therefore, genetic testing is necessary to confirm the diagnosis of KS and rule out other possible causes. The diagnosis of KS also faces some challenges and limitations, such as lack of standardized criteria or guidelines, ethical issues, and genetic counseling.

There is no cure for KS, but various interventions can help improve the quality of life and reduce the complications. The treatment of KS may include supportive care, pharmacological interventions, surgical interventions, educational interventions, and psychological interventions. Supportive care helps individuals with KS develop their motor, communication, and daily living skills. Pharmacological interventions treat or prevent some of the medical problems, such as seizures, sleep disorders, or respiratory infections. Surgical interventions correct some of the structural defects, such as heart defects, kidney defects, or hearing loss. Educational interventions help individuals with KS achieve their academic potential and social skills. Psychological interventions help individuals with KS cope with their emotional and mental health issues, such as autism spectrum disorders, apathy, or depression. The treatment of KS also requires regular follow-up and monitoring by a multidisciplinary team of specialists. The treatment of KS may also benefit from the advances in gene therapy in the future, which aims to correct or replace the faulty gene.

References

  1. Aydin H, et al. Kleefstra Syndrome. J Coll Physicians Surg Pak. 2022 Apr;32(4):S76-S78.
  2. Haseley A, et al. Kleefstra syndrome: Impact on parents. Disabil Health J. 2021 Apr;14(2):101018.
  3. Kleefstra T, de Leeuw N. Kleefstra Syndrome. 2010 Oct 5 [updated 2023 Jan 26]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.
  4. Kleefstra T, et al. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet. 2009 Sep;46(9):598-606.
  5. Colijn MA, et al. Psychosis and autism without functional regression in a patient with Kleefstra syndrome. Psychiatr Genet. 2023 Feb 1;33(1):34-36.
  6. Yoshida K, et al. Psychiatric manifestations of Kleefstra syndrome: a case report. Front Psychiatry. 2023 Jul 27;14:1174195.
  7. Okayasu T, et al. Otopathology in Kleefstra Syndrome: A Case Report. Laryngoscope. 2020 Aug;130(8):2028-2033.
  8. Noruzinia M, et al. Kleefstra Syndrome: The First Case Report From Iran. Acta Med Iran. 2017 Oct;55(10):650-654.
For research use only. Not intended for any clinical use.